News & Events

News & Events2022-10-31T18:45:01+00:00
1710, 2023

Donor kidneys carrying human transgenes results in life-supporting organ function and recipient survival of over two years

October 17th, 2023|Gene & Cell Therapy Testing, News|

eGenesis announced long-term survival data from a proof-of-concept study evaluating engineered porcine donor kidneys transplanted into a cynomolgus macaque model. This dataset will support advancement of the company’s lead candidate for kidney transplant, EGEN-2784, toward clinical development...

1010, 2023

Gene therapy biotech LEXEO Therapeutics files for IPO

October 10th, 2023|Gene & Cell Therapy Testing, News|

LEXEO Therapeutics will use the net proceeds from this offering to advance the clinical development of cardiac and neurological disease gene therapies. LEXEO Therapeutics, in its SEC filing, said it intends to use the net proceeds from this offering, together with their existing cash, to advance the clinical development of LX2006, LX2020 and LX1001...

709, 2023

Join Avance Biosciences™ at the BPI – Cell & Gene Therapy Conference – Sept 19-21

September 7th, 2023|Events, Gene & Cell Therapy Testing, News|

We are thrilled to announce that Avance Biosciences™ will be attending the highly anticipated Cell & Gene Therapy Manufacturing Conference, and we cordially invite you to join us! As a leader in advanced therapies, we understand the importance of staying at the forefront of cell and gene therapy innovation...

2908, 2023

FDA issues new draft guidelines on cell and gene therapy manufacturing changes

August 29th, 2023|FDA Guidance, Gene & Cell Therapy Testing, News|

Specifically, the guidance recommends conducting analytical comparability studies to provide scientific evidence of the impact that manufacturing changes may have on the safety, potency, and purity of human cellular and gene therapy products...

2308, 2023

First IND clearance for an allogeneic, off-the-shelf NK or CAR-T cell therapy candidate in autoimmune disease

August 23rd, 2023|CAR-T & Other Cell Therapy Testing, News|

Artiva Biotherapeutics announced today that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application for AlloNK®, in combination with rituximab for treatment of systemic lupus erythematosus in patients with active lupus nephritis...